Deferoxamine Treatment Protocol for Iron Overload

Standard Dosing Regimens

The American College of Cardiology recommends deferoxamine administration subcutaneously at 20-60 mg/kg/day for standard therapy, or intravenously at higher doses for patients with cardiac iron overload or heart failure 1, 2, 3
For long-term subcutaneous administration, deferoxamine is typically given at doses of 20-60 mg/kg/day via slow subcutaneous infusion over 8-12 hours, 5-7 days per week 1, 3
For patients with significant cardiac iron loading, higher doses and continuous administration may be required 4, 5
For acute cardiac decompensation or severe cardiac iron overload, continuous intravenous deferoxamine at higher doses is recommended for rapid removal of cardiac iron 1, 4

Subcutaneous administration is the preferred route for long-term maintenance therapy, typically administered via portable infusion pump over 8-12 hours, often overnight 1, 2
Intravenous administration is reserved for patients with severe cardiac iron overload or cardiac failure, allowing for continuous 24-hour therapy 4, 5
Combination therapy with deferoxamine and oral deferiprone (75-100 mg/kg/day) can be used for enhanced efficacy, particularly in patients with cardiac iron overload 4, 6

Serum ferritin should be monitored every 3 months, with a target of reducing levels to less than 1000 ng/mL 7, 8
For patients with transfusion-dependent thalassemia, cardiac T2* MRI should be performed annually to assess cardiac iron content 5, 6
Liver iron concentration should be monitored annually using MRI techniques 6
Regular cardiac assessments including electrocardiography and echocardiography should be performed annually starting at age 10 in transfusion-dependent patients 6

For patients with cardiac failure due to iron overload, continuous intravenous deferoxamine at higher doses (up to 50-60 mg/kg/day) is recommended 5
Combination therapy with deferoxamine and deferiprone at 75 mg/kg/day in divided doses can be considered for patients with cardiac failure due to iron overload 5, 6
Clinical stabilization may occur within 14 days but can take months 5

For maintenance therapy in transfusion-dependent patients, lifelong chelation is typically required 4, 5
After resolution of decompensated heart failure, treatment may need to continue for several years to completely remove cardiac iron 5
Treatment should be monitored by assessing clinical status, left ventricular ejection fraction, cardiac T2*, and ferritin trends 5